Press Release

​​​​​​Aging-US: Prognostic signature in uveal melanoma to guide clinical therapy

09-08-2021

Aging-US published a Special Collection on Eye Disease which included "Development and validation of an immune and stromal prognostic signature in uveal melanoma to guide clinical therapy" which reported that the tumor microenvironment is known to play an important role in uveal melanoma.

Reliable prognostic signatures are needed to aid high risk patients and improve prognosis. Immune and stromal scores were calculated by applying the "ESTIMATE" algorithm. The authors found that the median survival time of the low immune/stromal score group is longer than that of the high-score group.

Figure 8. Differential putative chemotherapeutic and immunotherapeutic response. (AG) The box plots of the estimated IC50 for the most sensitive chemotherapeutic drugs. (H) Submap analysis manifested that high risk group could be more sensitive to the programmed cell death protein 1 inhibitor (Bonferroni-corrected P = 0.02). *** P < 0.001.

Dr. Liang Hu from The Wenzhou Medical University said, "Uveal melanoma (UM) is the most common type of malignant tumor of the adult eye, and 50% of patients with UM will eventually die as a result."

Tumor microenvironment (TME) plays a pivotal role in cancer progression and therapeutic responses. Prognostic biomarkers related to TME may hold great promise in identifying molecular targets and guiding patient management. Immune and stromal cells are two major types suggested as crucial for the diagnostic and prognostic assessment of tumors. Scores can be calculated using the ESTIMATE algorithm to predict the infiltration of non-tumor cells in UM patients.

Scores can be calculated using the ESTIMATE algorithm to predict the infiltration of non-tumor cells in UM patients

The Hu Research Team concluded in their Aging-US Research Output, "our study reveals a comprehensive landscape of the immune and stromal microenvironment in UM, and provides a promising prognostic signature for UM. Patients with the high risk scores could benefit more from anti-PD-1 therapy and chemotherapy. Further investigations are needed to verify the accuracy in estimating prognoses and to test its clinical utility in patient management."

Full Text - https://www.aging-us.com/article/103779/text

Correspondence to: Liang Hu email: liang_hu@live.cn

Keywords: uveal melanoma, immune, stromal, prognosis

About Aging-US

Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research as well as topics beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, cancer, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR among others), and approaches to modulating these signaling pathways.

To learn more about Aging-US, please visit http://www.Aging-US.com or connect with @AgingJrnl

Aging-US is published by Impact Journals, LLC please visit http://www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact
18009220957x105
MEDIA@IMPACTJOURNALS.COM